Mortality Risk in Patients With Dementia Treated With Antipsychotics Versus Other Psychiatric Medications
- 1 October 2007
- journal article
- research article
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 164 (10) , 1568-1576
- https://doi.org/10.1176/appi.ajp.2007.06101710
Abstract
Mortality rates in the year following new antipsychotic medication starts for neuropsychiatric symptoms of dementia were compared with rates after starts of other psychiatric medications. The retrospective, cohort study used national data from the Department of Veterans Affairs (fiscal years 2001-2005) on patients older than 65 years who began outpatient treatment with psychiatric medication following a dementia diagnosis (N=10,615). Twelve-month mortality rates were compared in patients taking antipsychotics and those taking other psychiatric medications. The authors controlled for confounding by using multivariate models and propensity-scoring methods. Secondary analyses included a no-medication group and examination of mortality causes. All groups taking antipsychotics had significantly higher mortality rates (22.6%-29.1%) than patients taking nonantipsychotic medications (14.6%). Adjusted mortality risks for atypicals and for combined atypical and conventional antipsychotics were similar to those for conventional antipsychotics. The mortality risk was significantly lower for nonantipsychotic medications than conventional antipsychotics. Except for anticonvulsants, the adjusted risks for all individual classes of nonantipsychotics were significantly lower than the risk for antipsychotics. Mortality risks did not change over 12 months. The proportions of patients taking antipsychotics who died from cerebrovascular, cardiovascular, or infectious causes were not higher than rates for those taking nonantipsychotic psychiatric medications. Antipsychotic medications taken by patients with dementia were associated with higher mortality rates than were most other medications used for neuropsychiatric symptoms. The association between mortality and antipsychotics is not well understood and may be due to a direct medication effect or the pathophysiology underlying neuropsychiatric symptoms that prompt antipsychotic use.Keywords
This publication has 32 references indexed in Scilit:
- Antipsychotic Drugs in DementiaPublished by American Medical Association (AMA) ,2005
- Risk of Death With Atypical Antipsychotic Drug Treatment for DementiaJAMA, 2005
- Antipsychotic use in the elderly: shifting trends and increasing costsInternational Journal of Geriatric Psychiatry, 2005
- Pharmacological Treatment of Neuropsychiatric Symptoms of DementiaJAMA, 2005
- Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's diseaseInternational Journal of Geriatric Psychiatry, 2004
- Prevalence of Neuropsychiatric Symptoms in Dementia and Mild Cognitive ImpairmentJAMA, 2002
- The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patientsInternational Journal of Geriatric Psychiatry, 2002
- Are Patients at Veterans Affairs Medical Centers Sicker?Archives of internal medicine (1960), 2000
- Olanzapine Treatment of Psychotic and Behavioral Symptoms in Patients With Alzheimer Disease in Nursing Care FacilitiesArchives of General Psychiatry, 2000
- BEHAVIOUR DISTURBANCE AND OTHER PREDICTORS OF CARER BURDEN IN ALZHEIMER'S DISEASEInternational Journal of Geriatric Psychiatry, 1997